



Dr. med. Yordanka Tirefort

Specialist in blood cancer, general haematology, haemostasis (bleeding diathesis, thrombophilia) and general internal medicine, member of the Swiss Medical Association (FMH)

Languages

FR,EN

Work Experience

since 2018	Independent haematologist
since 2016	Chief medical director of the public foetoplacental blood bank of the Hôpitaux Universitaires de Genève
2018	Team leader of the Haematology and haemostasis department, SYNLAB Suisse diagnostic laboratories, Switzerland
2016–2018	Chief resident, in charge of ambulatory consultation for bone marrow stem cell transplant patients, Haematology department, Hôpitaux Universitaires de Genève
2016–2018	Team leader for the hematopoietic stem cell laboratory, Genetic and laboratory medicine department, Hôpitaux Universitaires de Genève. Promoted to Chief medical director (2013-2016)
2012–2018	Chief resident, Haematology department, Hôpitaux Universitaires de Genève
2015	Post-doctoral training in GMP, Haematology and bone marrow transplant department and the José Carreras Institut für Immun- und Gentherapie, Universitätsklinikum Regensburg, Germany
2008–2012	Junior doctor, Haematology department and Angiology and haemostasis unit, Hôpitaux Universitaires de Genève
2008–2003	Junior doctor, General internal medicine department and Internal medicine and rehabilitation department, Hôpitaux Universitaires de Genève
2001–2003	Research assistant, Angiology and haemostasis unit, Hôpitaux Universitaires de Genève (Doctoral thesis)
1998–2001	Junior doctor and research associate, Blood cell immunology laboratory, Immunohaematology and blood transfusion department, National Haematology Hospital, Sofia, Bulgaria

Education

2018	Diplôme d'études avancées – Clinical case management, Faculty of medicine, University of Geneva
2016	Certificate in clinical research (Clinical research investigator- GCP-ICP)
2016	FAMH federal medical specialism diploma in blood analysis
2012	FMH specialist diploma in haematology

2010	Degree in haemostatic conditions, Faculty of medicine, Montpellier, France
2009	FMH specialist diploma in internal medicine
2003	Doctorate in medicine from the University of Geneva
1997	Doctorate in medicine with commendation, Medical University of Sofia, Bulgaria

Competences

- Blood cancer (lymphoma, myeloma, leukaemia, myeloproliferative neoplasms, etc.)
- Benign haematological conditions, iron metabolism disorders, etc.
- Bone marrow transplants, post-surgical complications (infections, graft versus host disease, etc.)
- Haemostasis - bleeding conditions and thrombophilia
- Laboratory haematology; blood transfusions and haemovigilance procedures

Memberships

- European Haematology Association
- Société Francophone de Greffe de Moelle et de Thérapie Cellulaire
- National Commission Swisscord, Schweizerisches Rotes Kreuz
- International Cord Blood Association
- FMH
- AMGe (Association des Médecins du Canton de Genève)
- SVM (Société Vaudoise de Médecine)

Apprenticeship

2014-2018	Tutor for third-year medical students at the University of Geneva in practical assignments within the “Defences and immunity” unit As Chief resident of the Haematology department at the Hôpitaux Universitaires de Genève, involved in training of junior haematology doctors and medical teams providing care to patients with haematological conditions and bone marrow transplant patients.
-----------	---

Awards

2004 Prize from the Faculty of medicine of the University of Geneva for the best basic medicine thesis, awarded to the thesis titled “The effect of statins on endothelial activation driven by antiphospholipid antibodies”

Publications

Blum S; Dunet V, Comoli P, Tirefort Y,... Du Pasquier R. Progressive Multifocal Leukoencephalopathy Responsive to Withdrawal of Imatinib in a Patient with FIP1L1-PDGFR α Positive Myeloid Neoplasm. *Leuk and Lymphoma*. 2020;61:2226.

Tirefort Y. et Buser-Llinares R. Le don de sang de cordon sauve des vies. *Obstetrica* 2019, 3: 8-11.

Simonetta F, Pradier A , Bosshard C, Masouridi-Levrat S , Carole D , Tirefort Y, Roosnek E, Chalandon Y. Dynamics of Expression of Programmed Cell Death Protein-1 (PD-1) on T Cells After Allogeneic Hematopoietic Stem Cell Transplantation. *Front Immunol*. 2019;10:1034.

Tirefort Y. et Buser- Llinares R. Le don de sang de cordon sauve des vies. *Obstetrica* 2019, 3: 8-11.

Brisso E, Alsuliman T, Gruson B, Hermet Eric , Tirefort Y, Yakoub-Agha I, Alain S. Conduite à tenir devant une réactivation EBV et un syndrome lymphoprolifératif à EBV, une réactivation ou infection à CMV et à HHV-6 après allogreffe de cellules souches hématopoïétiques : recommandations de la SFGM-TC (mises à jour) [How to manage EBV reactivation and EBV-PTLD, CMV and human herpesvirus 6 reactivation and infection after allogeneic stem cell transplantation: A report of the SFGM-TC (update)]. *Bull Cancer*. 2017;104(12S):S181-S187.

Masouridi-Levrat S, Simonetta F, Beauverd Y, Tsopra O, Tirefort Y...,Chalandon Y. Excellent outcome with a high proportion of mixed chimerism in patients with severe aplastic anemia treated with partially T-cell-depleted peripheral hematopoietic stem cell transplants. *Bone Marrow Transplant*. 2016;51(6):860-862.

Raboud M,.... Tirefort Y, Masouridi-Levrat S, Chalandon Y. Impact of T-cell depletion on outcome of patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome. *Bone Marrow Transplant*. 2018;53(8):1072-1075. 2

Paiano S, Roosnek E, Tirefort Y...,Chalandon Y. Comparing Two Types of Rabbit ATG prior to Reduced Intensity Conditioning Allogeneic Hematopoietic SCT for Hematologic Malignancies. *Bone Marrow Research* 2015.

Simonetta F, Guerne PA, Tirefort Y..., Chalandon Y. Complete and sustained remission of spondyloarthritis after allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome. *Joint Bone Spine*. 2014.

Beauverd Y, Roosnek E, Tirefort Y..., Chalandon Y. Validation of the Disease Risk Index for Outcome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation after T Cell Depletion. *Biol Blood Marrow Transplant*. 2014; 20: 1322.

Tirefort Y, Pham XC,.... Samii K. A rare case of primary cutaneous follicle centre lymphoma presenting as a giant tumor of the scalp and combined with JAK2V617F positive essential thrombocythaemia. *Biomark Res*. 2014; 2: 7-12.

Tirefort Y, de Moerloose P, Neerman-Arbez M. Mutation of the translation initiation codon in FGA causes congenital afibrinogenaemia. *Blood Coagul Fibrinolysis*. 2012, 23: 556-558.

Tirefort Y, Uhr MR, Neerman-Arbez M, de Moerloose P. Identification of a novel F11 missense mutation (Ile463Ser) in a family with congenital factor XI deficiency. *Blood Coagul Fibrinolysis*. 2012, 23: 251-252.

Neerman-Arbez M, Tirefort Y, Moerloose P. Can mutations identified in congenital fibrinogen disorders explain the clinical manifestations? *J of Coagulation Disorders*, 2010; 2(2): 71-79.

Boehlen F, Tirefort-Dimitrova Y, de Moerloose P, Fontana P. Hémostase le point sur les nouveaux antithrombotiques. *Rev Médi Suisse*, 2010 Jan 20; 6 (232): 109-12.

de Moerloose P, Tirefort-Dimitrova Y,.... Boehlen F. Syndrome des anticorps antiphospholipides : beaucoup de nouveautés. *Rev Méd Suisse*, 2010 Feb 10; 6 (235): 298-301.

Dunoyer- Geindre S, Dimitrova Y (Tirefort),.... de Moerloose P. Fluvastatin increases the expression of adhesion molecules, MCP-1 and tissue factor in HUVEC stimulated by antiphospholipid antibodies. *J Thrombosis and Hemostasis* 2005; 93(2): 339-45.

Dimitrova Y (Tirefort), Geindre S,.... de Moerloose P. Effects of statins on adhesion molecule expression in endothelial cells. *J Thromb and Hemostasis* 2003(1): 2990-2999.

De Moerloose P, Dimitrova Y (Tirefort),.... Boehlen F. Maladie thrombo-embolique veineuse et thrombophilie: quel bilan demander pour quelles implications cliniques. *Médecine et Hygiène* 2002; S16-S20.

Regazzoni S, Luzuy F, Dimitrova Y (Tirefort), de Moerloose P. La protéine C: un nouveau traitement pour les sepsis et les méningococcémies sévères. *Médecine et Hygiène* 2002; 60: 42-46.

Dimitrova Y (Tirefort). Competitive assessment of the methods, used for the diagnosis of Immune Thrombopenic Purpura. *Annual Proceeding International Medical Association* 2000; 6: 189-191.

Dimitrova Y (Tirefort), Kalev I. Immune Thrombocytopenic Purpura - diagnosis and therapeutic approaches. *General Medicine* 2000; 2: 32-38.

Handouts Presentations

1. Tirefort Y, Simonetta F, ..., Chalandon Y. Impact of the different approaches of T cell depletion on NK cell subsets reconstitution after allogeneic Hematopoietic Stem Cell Transplantation EBMT 2015, Istanbul, P674.
2. Tirefort Y, Hauwel M, ..., Matthes T. Multiparameter flow cytometry (MPFC): role in diagnosis and follow-up of patients with plasma cell diseases, European and Swiss congress ESCIM 2014, Geneva, abstract Nr. A-648-0008-0093.
3. Tirefort Y, Pham X-C, ..., Samii K. A rare case of association of primary cutaneous follicle centre lymphoma presenting as a giant tumor of the scalp and essential thrombocythaemia, 81e assemblée de la SSMI/SSH 2013, Bâle, P 464.
4. Tirefort Y, Roosnek E, ..., Chalandon Y. Prognostic significance of EBMT risk score for the outcome of allogeneic hematopoietic stem cell transplantations after T-cell depletion. Communication orale SSH 2012.
5. Paiano S, Roosnek E, Tirefort Y, ..., Chalandon Y. A study comparing two types of rabbit ATG as part of pre-transplant conditioning for allogeneic HSCT for hematologic malignancies: Earlier relapse with Thymoglobulin as compared to ATG-F. EBMT 2011.
6. Dimitrova Y (Tirefort), Dunoyer-Geindre S, Kruithof E, Reber G, de Moerloose P. Effects of statins on adhesion molecules expression in endothelial cells. XIX Congress of the International Society on Thrombosis and Haemostasis. Birmingham, UK. P0155, ref. 4415.
7. Dunoyer-Geindre S, Dimitrova Y (Tirefort), Kruithof EKO, Reber G, de Moerloose P. Effects of statins on endothelial activation by tumor necrosis factor. X International Congress on Antiphospholipid Antibodies. Sicile, Italie. Lupus 2002; 11: 590.
8. Dimitrova Y (Tirefort). Recurrent anti-HPA-Ia induced neonatal allo-immune thrombocytopenia in one family. Congrès de la Société française de Thrombose et Hémostase, Genève, 2001.

Accreditation

[Clinique Générale-Beaulieu](#)

[Clinique de Genolier](#)

Specialties

[Oncology](#)

[Hematology](#)

Contact

Générale-Beaulieu Swiss Oncology Network

Chemin de Beau-Soleil 20

1206 Genève

T +41 22 839 57 99

ytirefort@beaulieu.ch

[Download vCard](#)

Clinique de Genolier

Route du Muids 3

1272 Genolier

ytirefort@genolier.net

[Download vCard](#)